A review compared the effectiveness and safety of dabigatran, rivaroxaban, and apixaban for the prevention of stroke in patients with atrial fibrillation.
Atrial fibrillation is common not only in ischemic stroke patients, but among those who have experienced transient ischemic attack, according to a recent study.
Researchers have developed and validated a generalizable risk score that can provide absolute risk estimates for sudden cardiac death based on 12 independent risk factors.